000087774 001__ 87774
000087774 005__ 20230914083245.0
000087774 0247_ $$2doi$$a10.3390/cells8111407
000087774 0248_ $$2sideral$$a116070
000087774 037__ $$aART-2019-116070
000087774 041__ $$aeng
000087774 100__ $$0(orcid)0000-0003-1508-6516$$aIglesias, Eldris$$uUniversidad de Zaragoza
000087774 245__ $$aUridine Prevents Negative Effects of OXPHOS Xenobiotics on Dopaminergic Neuronal Differentiation
000087774 260__ $$c2019
000087774 5060_ $$aAccess copy available to the general public$$fUnrestricted
000087774 5203_ $$aNeuronal differentiation appears to be dependent on oxidative phosphorylation capacity. Several drugs inhibit oxidative phosphorylation and might be detrimental for neuronal differentiation. Some pregnant women take these medications during their first weeks of gestation when fetal nervous system is being developed. These treatments might have later negative consequences on the offspring’s health. To analyze a potential negative effect of three widely used medications, we studied in vitro dopaminergic neuronal differentiation of cells exposed to pharmacologic concentrations of azidothymidine for acquired immune deficiency syndrome; linezolid for multidrug-resistant tuberculosis; and atovaquone for malaria. We also analyzed the dopaminergic neuronal differentiation in brains of fetuses from pregnant mice exposed to linezolid. The drugs reduced the in vitro oxidative phosphorylation capacity and dopaminergic neuronal differentiation. This differentiation process does not appear to be affected in the prenatally exposed fetus brain. Nevertheless, the global DNA methylation in fetal brain was significantly altered, perhaps linking an early exposure to a negative effect in older life. Uridine was able to prevent the negative effects on in vitro dopaminergic neuronal differentiation and on in vivo global DNA methylation. Uridine could be used as a protective agent against oxidative phosphorylation-inhibiting pharmaceuticals provided during pregnancy when dopaminergic neuronal differentiation is taking place.
000087774 536__ $$9info:eu-repo/grantAgreement/ES/DGA/B33-17R$$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI17-00021$$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI17-00166
000087774 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000087774 590__ $$a4.366$$b2019
000087774 591__ $$aCELL BIOLOGY$$b70 / 194 = 0.361$$c2019$$dQ2$$eT2
000087774 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000087774 700__ $$0(orcid)0000-0002-8585-6371$$aBayona-Bafaluy, M. Pilar$$uUniversidad de Zaragoza
000087774 700__ $$aPesini, Alba
000087774 700__ $$0(orcid)0000-0003-0145-3020$$aGarrido-Pérez, Nuria$$uUniversidad de Zaragoza
000087774 700__ $$0(orcid)0000-0002-3587-6622$$aMeade, Patricia$$uUniversidad de Zaragoza
000087774 700__ $$0(orcid)0000-0002-9779-8826$$aGaudó, Paula$$uUniversidad de Zaragoza
000087774 700__ $$0(orcid)0000-0002-1426-3958$$aJiménez-Salvador, Irene$$uUniversidad de Zaragoza
000087774 700__ $$0(orcid)0000-0003-1770-6299$$aMontoya, Julio$$uUniversidad de Zaragoza
000087774 700__ $$0(orcid)0000-0002-0269-7337$$aRuiz-Pesini, Eduardo$$uUniversidad de Zaragoza
000087774 7102_ $$11002$$2060$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Bioquímica y Biolog.Mole.
000087774 773__ $$g8, 11 (2019), 1407 [20 pp.]$$pCells$$tCells$$x2073-4409
000087774 8564_ $$s1671065$$uhttps://zaguan.unizar.es/record/87774/files/texto_completo.pdf$$yVersión publicada
000087774 8564_ $$s473257$$uhttps://zaguan.unizar.es/record/87774/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000087774 909CO $$ooai:zaguan.unizar.es:87774$$particulos$$pdriver
000087774 951__ $$a2023-09-13-10:50:07
000087774 980__ $$aARTICLE